drugset
drugset / Trial / NCT04690036

PD-1 Antibody for Reactive EBV After BMT

NCT04690036 ↗

Phase 0 Unknown 20 enrolled Beijing Friendship Hospital
NaSingle-groupOpen-labelTreatment

Summary

PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH

Timeline

Start
2021-07-01
Primary completion
2023-01-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 3 mg/kg —

Indications

Epstein-Barr virus infection disease related to transplantation